acasadtoglad-shiva.blogspot.com
The biopharmaceutical industry has argued that the five yeard of protection offered by Waxmanin H.R. 1427 woulfd stifle innovation. But the in a reportf earlier this month said the 12 to 14 yearzs that the industry has said publicly that it wantsx also would hurt innovation anddelaty patients’ access to cheaper drugs. Eshoo’xs H.R. 1548 calls for a 12-yeat period of data exclusivity, basically protectinyg the patents covering innovativebiotech therapies.
In a letterr to Waxman, Nancy-Ann DeParle, Obama’s health-care refork director, and budget director Peter Orszagsaid “the seven-year policy in the FY 2010 budgetf is a generous compromise betweehn what the FTC research has concludecd and what the pharmaceutical industry has , however, said it is “extremely concerned” that the seven-yeaer plan is “a risky shortcut to “We believe this abbreviated period will undermine the incentives necessarty for continued biotech research into breakthroughn medicines and cures for diseases such as cancer, multiple sclerosis, Alzheimer’s and HIV/AIDS as well as unmeft medical needs,” BIO President and CEO Jim Greenwood said in a
No comments:
Post a Comment